Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 10, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 1,845,000 ordinary shares.
- Repurchase Price: 1,308.9122 pence per share.
- Treasury Shares Held: 387,222,158 shares (representing 6.87% of total voting rights).
- Shares in Issue: 5,635,580,669 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the increase in the company's Treasury shareholding following the open market purchase on September 10, 2007. This transaction reduced the number of shares in issue available to the public while increasing the proportion of voting rights held in Treasury.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provisions.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,635,580,669) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (387,222,158) and its impact on the 6.87% voting rights representation.
- Note that this filing is a regulatory notification of a share buyback and does not contain financial performance data for the period.